LeMaitre Vascular, Inc. (NASDAQ:LMAT) Q3 2023 Earnings Call Transcript

Page 5 of 5

And then, the other piece would be the transition of manufacturing for Omniflow and for CardioCel. And those start out pretty inefficient as we’ve discussed before and, hopefully, and we think we can make some good progress on those as we move forward through the quarters. So we might get some good answers there as well. So we’ll see where that all winds up for next year, when we give you guidance.

Michael Petusky: Got it. Sounds great. Thanks, and really congratulations. This was another excellent quarter. Thanks.

George LeMaitre: Thanks a lot, Mike.

Joseph Pellegrino: Thanks, Mike.

Operator: Thank you. Ladies and gentlemen, this does conclude today’s conference. We would like to thank you for participating, and you may now disconnect. Everyone, have a great day.

Follow Lemaitre Vascular Inc (NASDAQ:LMAT)

Page 5 of 5